Protalix BioTherapeutics, Inc. (PLX) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
PLX currently has 79.8M outstanding shares. with minimal authorized share overhang for future dilution. The company has diluted shareholders by 15.46% over the past 2 years through share issuances.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 13, 2026 |
10-Q filing | 79.8M shares outstanding |
80M | 0 |
| Mar 18, 2026 |
10-K filing | 82.4M shares outstanding |
82M | 0 |
| Nov 13, 2025 |
10-Q filing | 78.2M shares outstanding |
78M | 0 |
| Aug 14, 2025 |
S-3/A filing: This is an S-3/A filing to register additional securities, but the specifics of the offering are not detailed in the provided content. |
77M | 0 |
| Aug 14, 2025 |
10-Q filing | 77.7M shares outstanding |
78M | 0 |
| May 09, 2025 |
10-Q filing | 76.6M shares outstanding |
77M | 0 |
| Apr 28, 2025 |
S-3 filing: The filing is an S-3 registration statement for the potential offering of common stock, preferred stock, debt securities, and warrants up to an aggregate amount of $100,000,000. |
78M | 0 |
| Mar 17, 2025 |
10-K filing | 78.0M shares outstanding |
78M | 0 |
| Nov 14, 2024 |
10-Q filing | 73.3M shares outstanding |
73M | 0 |
| Aug 14, 2024 |
10-Q filing | 73.2M shares outstanding |
73M | 0 |
| May 10, 2024 |
10-Q filing | 73.0M shares outstanding |
73M | 0 |
| Mar 14, 2024 |
10-K filing | 73.0M shares outstanding |
73M | 0 |
| Nov 06, 2023 |
10-Q filing | 65.8M shares outstanding |
66M | 0 |
| Aug 07, 2023 |
10-Q filing | 71.6M shares outstanding |
72M | 0 |
| May 04, 2023 |
10-Q filing | 65.4M shares outstanding |
65M | 0 |
| Feb 27, 2023 |
10-K filing | 57.4M shares outstanding |
57M | 0 |
| Nov 14, 2022 |
10-Q filing | 47.6M shares outstanding |
48M | 0 |
| Aug 15, 2022 |
10-Q filing | 46.6M shares outstanding |
47M | 0 |
| May 16, 2022 |
10-Q filing | 45.8M shares outstanding |
46M | 0 |
| Apr 20, 2022 |
S-3 filing: The company is filing an S-3 to offer common stock, preferred stock, debt securities, and warrants with an aggregate public offering price of up to $100,000,000. |
35M | 0 |
| Mar 31, 2022 |
10-K filing | 34.8M shares outstanding |
35M | 0 |
| Nov 15, 2021 |
10-Q filing | 43.8M shares outstanding |
44M | 0 |
| Aug 16, 2021 |
10-Q filing | 45.6M shares outstanding |
46M | 0 |
| May 14, 2021 |
10-Q filing | 45.4M shares outstanding |
45M | 0 |
| Mar 30, 2021 |
10-K filing | 14.8M shares outstanding |
15M | 0 |
| Feb 16, 2021 |
8-K filing: Protalix BioTherapeutics, Inc. completed an offering of 7,608,695 shares of common stock at $4.60 per share, resulting in net proceeds of approximately $32.7 million. The underwriters also have an option to purchase up to an additional 1,141,304 shares. Following the completion of the offering, the Company will have 44,241,527 shares issued and outstanding (or 45,382,831 shares if the underwriters exercise their option). |
44M | 0 |
| Oct 29, 2020 |
10-Q filing | 33.3M shares outstanding |
33M | 0 |
| Aug 10, 2020 |
10-Q filing | 32.4M shares outstanding |
32M | 0 |
| Jun 01, 2020 |
10-Q filing | 32.4M shares outstanding |
32M | 0 |
| Apr 17, 2020 |
S-3 filing: This is an S-3 filing to register the resale of common stock by selling stockholders. |
N/A | 0 |
| Mar 18, 2020 |
8-K filing: Protalix BioTherapeutics, Inc. completed a $43.7 million private placement, issuing 17,604,423 unregistered shares of common stock at $2.485 per share and warrants to purchase an additional 17,604,423 shares at $2.36 per share. ($43.7M proceeds) |
N/A | 0 |
| Mar 12, 2020 |
10-K filing | 14.8M shares outstanding |
15M | 0 |
| Mar 12, 2020 |
8-K filing: Protalix BioTherapeutics, Inc. entered into purchase agreements to issue and sell approximately 17.6 million shares of common stock at a price of $2.485 per share, with warrants to purchase one share of common stock at an exercise price of $2.36. ($43.7M proceeds) |
N/A | 0 |